Chapter

Therapy of Myasthenia Gravis

Daniel B. Drachman

in Myasthenia Gravis and Myasthenic Disorders

Second edition

Published on behalf of © 2012 by Mayo Foundation for Medical Education and Research

Published in print March 2012 | ISBN: 9780199738670
Published online April 2013 | e-ISBN: 9780199322848 | DOI: http://dx.doi.org/10.1093/med/9780199738670.003.0006

Series: Contemporary Neurology Series

Therapy of Myasthenia Gravis

Show Summary Details

Preview

As a result of important advances in understanding the pathogenesis of MG, and developments in immunological treatment strategies, the outlook for myasthenic patients has improved dramatically in recent years. At present, with optimal treatment, the mortality rate is essentially zero, and nearly all myasthenic patients can be returned to full productive lives.1 Therapy of MG is based directly on concepts of the pathophysiology and immunology of MG. Therefore, successful practical treatment requires a clear understanding of both the physiological abnormalities at the neuromuscular junction (NMJ) and the immunological basis of the autoimmune attack, detailed in Chapters 2 and 4, and briefly outlined below.

Chapter.  16717 words.  Illustrated.

Subjects: Neurology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.